Pharmx Posts Record $7.5M Revenue Amid Strategic Growth Push
Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.
- FY25 revenue up 13% to $7.5 million
- EBITDA declined 13% to $1.61 million due to growth investments
- Cash reserves strong at $4.2 million
- Launched Supplier and Pharmacy Portals and AI analytics platform
- Key partnerships expanded in Australia and New Zealand
Record Revenue Growth
Pharmx Technologies Limited (ASX – PHX) has delivered a robust financial performance for the year ended 30 June 2025, reporting total revenues of $7.5 million, a 13% increase compared to the previous year. This growth was underpinned by an expanded network of supplier partners and increased transaction volumes across its pharmacy ordering platform, reinforcing Pharmx’s position as a leading player in the ANZ pharmaceutical technology sector.
Investment Impact on Profitability
Despite the revenue uplift, the company’s EBITDA fell by 13% to $1.61 million. This decline reflects significant strategic investments in product development, sales and marketing capabilities, and IT infrastructure. These expenditures supported the launch of new Supplier and Pharmacy Portals and the enhancement of the Marketplace platform, positioning Pharmx for sustained long-term growth. The company’s strong cash position of $4.2 million at year-end provides a solid financial foundation to continue these initiatives.
Operational and Strategic Advances
Operationally, Pharmx expanded its supplier partners by 16% and total accounts by 7%, driving an 11% increase in recurring revenue. Noteworthy is the company’s growth in New Zealand, where supplier revenue surged 58% year-on-year, bolstered by a strategic agreement with Toniq, a dominant pharmacy point-of-sale software provider. This deal opens access to nearly all New Zealand pharmacies, unlocking significant future revenue potential.
Pharmx also renewed its partnership with Diabetes Australia to support the National Diabetes Services Scheme, reinforcing its role in healthcare infrastructure. The early termination of a revenue share agreement with Alchemy Healthcare has cleared the way for focused investment in the Marketplace intellectual property, aligning with Pharmx’s broader Single Platform strategy.
Technology and Innovation Focus
FY25 saw the rollout of several key technological advancements, including AI-powered analytics adopted by 13 suppliers, major Marketplace updates, and infrastructure upgrades enhancing data flow and security. The company also implemented new AI tools, CRM systems, and automated marketing platforms, alongside a team restructure aimed at boosting productivity and efficiency.
CEO Perspective and Outlook
CEO Tom Culver expressed satisfaction with the year’s results, highlighting the company’s commitment to transforming healthcare connectivity through innovation. He emphasized Pharmx’s dual focus on system performance and security, and the strategic use of AI and automation to drive growth. With a strong balance sheet and a clear roadmap, Pharmx is well-positioned to capitalize on evolving market opportunities across Australia and New Zealand.
Bottom Line?
Pharmx’s strategic investments and platform innovations set the stage for accelerated growth, but investors will watch closely for a rebound in profitability.
Questions in the middle?
- How quickly will Pharmx’s EBITDA recover as investments mature?
- What impact will the Toniq partnership have on Pharmx’s New Zealand market share?
- How will AI and automation initiatives translate into competitive advantage and revenue growth?
